Mangalam Drugs & Organics Limited
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Mangalam Drugs & Organics Limited's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 18% to $3,673,536,000. Profit margin reached -2%. Total operating expenses were $162,228,000.
Profit Margin
| 2010 | 1.12B | 18.23M | 1.62% |
|---|---|---|---|
| 2011 | 1.31B | 24.23M | 1.85% |
| 2012 | 1.53B | 6.33M | 0.41% |
| 2015 | 2.20B | 61.41M | 2.78% |
| 2016 | 2.95B | 160.33M | 5.43% |
| 2018 | 2.75B | 198.89M | 7.21% |
| 2019 | 2.23B | -80.30M | -3.59% |
| 2021 | 3.79B | 279.70M | 7.36% |
| 2022 | 4.47B | 196.57M | 4.39% |
| 2024 | 3.67B | -90.71M | -2.47% |
MANGALAM.NS Income Statement (2010 – 2023)
| 2023 | 2021 | 2020 | 2018 | 2017 | 2015 | 2014 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 3.67B | 4.47B | 3.79B | 2.23B | 2.75B | 2.95B | 2.20B | 1.53B | 1.31B | 1.12B |
Cost of revenue | 3.48B | 3.11B | 2.55B | 1.55B | 1.65B | 2.28B | 1.79B | 1.22B | 1.13B | 972.26M |
Gross profit | 188.12M | 1.36B | 1.24B | 687.22M | 1.10B | 663.47M | 408.35M | 304.09M | 183.43M | 150.65M |
Operating exp. | ||||||||||
Research and development | 0 | 29.64M | 22.53M | 37.15M | 32.04M | 12.81M | 7.92M | 0 | 0 | 0 |
Selling and marketing | -218.30M | 72.94M | 75.18M | 34.56M | 42.12M | 59.12M | 54.67M | 21.72M | 22.33M | 15.36M |
Total operating expenses | 162.22M | 1.00B | 798.87M | 660.77M | 700.22M | 330.60M | 245.43M | 191.07M | 84.8M | 68.98M |
Operating income | 27.45M | 388.05M | 441.98M | 26.45M | 402.84M | 332.87M | 162.92M | 113.02M | 98.63M | 81.66M |
Other income (expenses), net | -138.19M | -110.72M | -48.05M | -83.82M | -109.37M | -94.00M | -102.70M | -101.64M | 68.59M | 59.63M |
Income before tax | -110.73M | 277.33M | 395.19M | -57.37M | 293.47M | 240.16M | 60.08M | 11.37M | 30.03M | 22.03M |
Income tax expense | -20.01M | 80.75M | 115.48M | 22.93M | 94.57M | 79.82M | -1.32M | 5.04M | 5.8M | 3.8M |
Net income | -90.71M | 196.57M | 279.70M | -80.30M | 198.89M | 160.33M | 61.41M | 6.33M | 24.23M | 18.23M |
Earnings per share | ||||||||||
Basic EPS | -5.73 | 12.42 | 17.67 | -5.07 | 12.57 | 11.15 | 4.66 | 0.48 | 1.84 | 1.38 |
Diluted EPS | -5.73 | 12.42 | 17.67 | -5.07 | 12.57 | 10.13 | 4.66 | 0.48 | 1.84 | 1.38 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |